As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.
The approved indications for brand-name GLP-1s:
Bydureon (exenatide)
- Type 2 diabetes in patients ages 10 years and older
Byetta (exenatide)
- Type 2 diabetes in adults
Mounjaro (tirzepatide)
- Type 2 diabetes in adults
Ozempic (semaglutide)
- Type 2 diabetes in adults
- To reduce the risk of major adverse cardiovascular events in diabetic adults with cardiovascular disease
- To reduce the risk of worsening kidney disease in diabetic adults with chronic kidney disease
Rybelsus (semaglutide)
- Type 2 diabetes in adults
- To reduce the risk of major adverse cardiovascular events in diabetic adults at high risk for these events
Saxenda (liraglutide)
- Chronic weight management in obese patients ages 12 years and older
- Chronic weight management in overweight adults with at least one weight-related comorbid condition, such as hypertension, Type 2 diabetes or dyslipidemia
Soliqua (lixisenatide and insulin glargine)
- Type 2 diabetes in adults
Trulicity (dulaglutide)
- Type 2 diabetes in patients ages 10 years and older
- To reduce the risk of major adverse cardiovascular events in diabetic adults with cardiovascular disease or multiple cardiovascular risk factors
Victoza (liraglutide)
- Type 2 diabetes in patients ages 10 years and older
- To reduce the risk of major adverse cardiovascular events in diabetic adults with cardiovascular disease
Wegovy (semaglutide)
- Long-term weight loss in obese patients ages 12 years and older
- Long-term weight loss in overweight adults with at least one weight-related comorbid condition
- To reduce the risk of major adverse cardiovascular events in adults with cardiovascular disease and are either obese or overweight
- To treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis
Xultophy (liraglutide and insulin degludec)
- Type 2 diabetes in adults
Zepbound (tirzepatide)
- Long-term weight loss in obese or overweight adults with at least one weight-related comorbid condition
- To treat moderate to severe obstructive sleep apnea in obese adults
The approved indications for generic GLP-1s:
- Amneal Pharmaceuticals’ exenatide, a therapeutical equivalent for Novo Nordisk’s Byetta, is approved to improve glycemic control in adults with Type 2 diabetes
- Hikma Pharmaceuticals’ liraglutide, a therapeutical equivalent for Novo Nordisk’s Victoza, is approved to improve glycemic control in patients ages 10 years and older with Type 2 diabetes
- Teva Pharmaceuticals’ liraglutide, a therapeutical equivalent for Novo Nordisk’s Victoza, is approved to improve glycemic control in patients ages 10 years and older with Type 2 diabetes
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
